LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial Of DAY101 Monotherapy Versus Standard Of Care Chemotherapy In Patients With Pediatric Low-Grade Glioma Harboring An Activating RAF Alteration Requiring First-Line Systemic Therapy
PI: Dr. Nirav Thacker Study contact: [email protected] Study contact full name: Isabelle Laforest Research Area: Cancer Who to contact regarding participating: Isabelle Laforest Lay Summary: This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 study to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus SoC chemotherapy in patients with pediatric low-grade glioma … Read more